Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1^st January 2022.
 
This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through Services Australia website.

Chronic lymphocytic leukaemia and small lymphocytic lymphoma
Idelalisib for chronic lymphocytic leukaemia and small lymphocytic lymphoma has had an amendment to the authority level for initial treatment. Authority applications for initial and continuing treatment can be made either in real time using HPOS or by telephone.
 
Refractory follicular B-Cell non-Hodgkin’s lymphoma
Idelalisib for refractory follicular B-Cell non-Hodgkin’s lymphoma has had amendments to the authority level for initial and continuing treatment. Authority requests for initial applications can be made either in real time using HPOS or by telephone. Continuing applications are Authority Required (STREAMLINED).
 
Locally advanced or metastatic breast cancer
Palbociclib, 75 mg, 100 mg, 125 mg tablets are now PBS listed for locally advanced or metastatic breast cancer. Authority applications for initial and continuing treatment can be made either in real time using HPOS or by telephone.
 
Severe established osteoporosis
Romosozumab and teriparatide for severe established osteoporosis has had a change of restriction to allow previous non-PBS patients eligibility to receive PBS-subsidised treatment with these medicines. Authority applications for romosozumab for initial and continuing treatment can be made either in real time using HPOS or by telephone. Initial and continuing applications for teriparatide are Authority Required (STREAMLINED).
 
Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Ibrutinib
Ibrutinib for chronic lymphocytic leukaemia or small lymphocytic lymphoma has had a change to the existing PBS prescribing instructions to update the wording from ‘17p chromosomal deletions demonstrate by Fluorescence in situ hybridisation (FISH)’ to ‘17p chromosomal deletions demonstrated by Medicare Benefits Schedule (MBS) listed test’.
 
Chronic heart failure
Dapagliflozin 10 mg strength is now PBS listed for chronic heart failure. This item is Authority Required (Streamlined).
 
Metastatic colorectal cancer
Encorafenib is now PBS listed for metastatic colorectal cancer. Cetuximab for metastatic colorectal cancer has had restriction changes to allow treatment in combination with encorafenib. Initial and continuing applications are Authority Required (STREAMLINED). 

1 January 2022 delisted PBS listings
 
Tipranavir (Aptivus)
Tipravavir 250 mg capsule, 120 has been delisted from the PBS. The standard 12 months’ “Supply Only” will apply.
 
Teriparatide (Forteo)
Teriparatide 250 microgram/mL injection, 2.4 mL pen device has been delisted from the PBS with 5 months “Supply Only” arrangement.

To learn more about these updates, please contact Services Australia directly.

At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.

Follow our LinkedIn and Facebook pages for more information.